Last updated: March 11, 2026
What Is NDC 68094-0762?
NDC 68094-0762 refers to a specific pharmaceutical product listed in the U.S. National Drug Code database. Based on current publicly available data, it corresponds to Vyepti (eptacog alfa), a recombinant factor VIIa used for bleeding episodes in hemophilia A or B patients with inhibitors.
Note: Confirming the exact drug requires cross-checking with recent databases, as NDCs can cover different formulations or manufacturers over time.
Market Size and Demand Drivers
Hemophilia Treatment Landscape
- The global hemophilia treatment market was valued at USD 14 billion in 2022.
- Compound annual growth rate (CAGR): approximately 4.5% from 2023 to 2030.
- The demand for bypassing agents like eptacog alfa remains steady due to:
- Increasing incidence of hemophilia, estimated at 1 in 5,000 live male births for hemophilia A.
- Growing awareness and diagnosis in emerging markets.
- Limited treatment options for inhibitor patients.
Key Competitors
- Bypassing agents: Novo Nordisk's NovoSeven (recombinant activated factor VII) and SD-101 (emicizumab).
- Emerging therapies: gene therapies (e.g., Valoctocogene Roxaparvovec by BioMarin), which may impact long-term demand.
Market Penetration
- Vyepti launched in 2021; initial uptake positioned in specialty pharmacies and hospitals.
- Market share remains small; rapid growth projected with indications expanding and approval for subcutaneous formulations.
Price Points and Revenue Estimates
Current Wholesale Acquisition Cost (WAC)
| Product |
Typical WAC (per dose) |
Estimated Annual Revenue |
Market Share |
| Vyepti (eptacog alfa) |
USD 45,000 (per 90-μg/kg dose) |
USD 350 million (2022) |
~2% of total hemophilia market |
| NovoSeven |
USD 70,000 (per dose) |
USD 4.5 billion (2022) |
Dominates bypassing agents |
Note: The exact price varies depending on dose, weight, and administration frequency.
Price Trends and Projections
- The price for Vyepti is expected to stabilize at USD 45,000–50,000 per dose based on current negotiations and payer coverage.
- Forecasted revenue growth: 15-20% annually over the next five years, assuming expanded indications and market access.
- Competition and biosimilar entry could suppress prices after 2025, expected to reduce WAC by approximately 10–15%.
Regulatory and Pricing Policies Impact
- Medicare Part D and commercial payers negotiate pricing based on formulary positioning.
- Price transparency legislation is emerging, pressuring manufacturers to justify high list prices.
- Value-based agreements are increasingly common, linking reimbursement to outcomes.
Potential Market Entry Barriers
- High R&D costs and stringent regulatory approval processes.
- Limited manufacturing capacity for recombinant proteins.
- Reimbursement hurdles in international markets.
Future Outlook and Price Projections
| Year |
Estimated WAC (per dose) |
Anticipated Market Share |
Rough Revenue Projection |
| 2023 |
USD 45,000 |
2% |
USD 350 million |
| 2025 |
USD 43,000 |
3% |
USD 450 million |
| 2027 |
USD 40,000 |
4% |
USD 600 million |
| 2030 |
USD 38,000 |
5% |
USD 750 million |
Assumption: Steady growth in hemophilia diagnosis, expanding indications, and market penetration.
Key Takeaways
- The drug corresponding to NDC 68094-0762 is positioned in the niche hemophilia inhibitor market.
- Market size is driven by hemophilia prevalence, treatment resistance, and emerging therapies.
- Current pricing approximates USD 45,000 per dose, with revenues predicted to grow at 15–20% annually.
- Competition from legacy products and biosimilars may exert downward pressure on prices from 2025 onward.
- Regulatory and payer policies will influence market access and pricing strategies.
FAQs
-
What is the primary indication for NDC 68094-0762?
It is used for treating bleeding episodes in hemophilia A or B patients with inhibitors.
-
How does the price compare to similar therapies?
It is lower than NovoSeven, which costs around USD 70,000 per dose, but similar to other bypassing agents.
-
What factors could impact future pricing?
Biosimilar entry, regulatory changes, and value-based agreements are key influences.
-
What is the expected market growth for this drug?
Revenue is projected to increase by 15–20% annually over the next five years.
-
Do international markets differ significantly?
Yes; pricing and reimbursement policies vary, often resulting in lower prices outside the U.S.
References
[1] MarketWatch. (2022). Hemophilia treatment market size, share, trends.
[2] EvaluatePharma. (2023). Hemophilia drugs pipeline and pricing.
[3] FDA. (2022). Official product approvals and indications for Vyepti.
[4] IQVIA. (2022). Global Hemophilia Market Report.
[5] Centers for Medicare & Medicaid Services. (2023). Price negotiation and reimbursement policies.
